Replies to post #8212 on Momenta Pharmaceuticals, Inc. (MNTA)

[pollyvonwog]

. For 2012 we are raising our EPS estimate from $0.09 to $0.25, mainly driven by $15M in upfront fee which we assume will be recognized in 2012." ( WTF are they referring too?)

Good question... Also, what's with their .09 est for the year before the upfront payment, which is the wrong number anyway? Are they anticipating ampha winning the appeal or something?

[DewDiligence]

[UBS]:…raising EPS estimate from $0.09 to $0.25, mainly driven by $15M in upfront fee which we assume will be recognized in 2012.

[jbog]: WTF are they referring too?

UBS must have confused the BAX deal with one of MNTA’s other partnership transactions. The up-front amount in the BAX deal is $33M, as can be seen from the biobucks table in #msg-70258421.

[t57]

do they just make this stuff up?

I can't find anything to support these comments.
Revenues of $26M????


" UBS Investment Research has given the company a buy rating and is expecting Momenta to generate revenues of $26 million by the end of the year.
Due to its strong analytical technology platform, UBS expects Momenta to have a brilliant success in the follow-on-biologics space where it will likely become a partner of choice for bigger pharmaceutical companies

[dav1234]

Must be referring to a monthly eps of .19—.25,lol!,that analyst shouldn't have a job on monday